Clinical Study
Methotrexate Associated Renal Impairment Is Related to Delayed Elimination of High-Dose Methotrexate
Table 2
Possible parameters related to CCR decrease > 50%.
| Parameters | Standard | Number ratio | Relative risk | 95% CI | value |
| Age ≥10 years | <10 years | 41 versus 132 | 0.81 | 0.09–7.30 | 0.852 | Body surface area ≥1.0 m2 | <1.0 m2 | 51 versus 122 | 1.77 | 0.24–12.96 | 0.573 | MTX dosage (≥5 g/m2) | <5 g/m2 | 60 versus 113 | 0.98 | 0.24–4.10 | 0.979 | S-creatinine 0 h ≥35 μmol/L | <35 μmol/L | 58 versus 115 | 0.31 | 0.07–1.44 | 0.134 | _24 h ≥65 μmol/L | <65 μmol/L | 74 versus 99 | 0.83 | 0.26–2.65 | 0.758 | Delayed MTX elimination | Normal elimination | 53 versus 120 | 8.07 | 2.57–25.32 | <0.001 |
|
|
S-creatinine 0 h: serum creatinine level before MTX infusion; _24 h: serum MTX concentration in 24 hours after MTX infusion.
|